Cargando…

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting

Detalles Bibliográficos
Autores principales:	Marzolini, Maria A. V., Mehra, Varun, Thomson, Kirsty J., Tholouli, Eleni, Bloor, Adrian J. C., Parker, Anne, Lovell, Richard, Orchard, Kim, Publicover, Amy, Nicholson, Emma, Snowden, John A., Byrne, Jennifer, Khan, Anjum, Gilleece, Maria H., Errico, Gerardo, Lozano, Sara, Hurst, Erin, Duncan, Nick, Pirrie, Jennifer, Crea, Philip, Carpenter, Ben, Pagliuca, Antonio, Peggs, Karl S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579255/ https://www.ncbi.nlm.nih.gov/pubmed/34614515 http://dx.doi.org/10.1182/bloodadvances.2021005637

Ejemplares similares

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
por: Otunuga, Olusegun Michael, et al.
Publicado: (2023)

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
por: Galleu, Antonio, et al.
Publicado: (2019)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
por: Menzel, Karsten, et al.
Publicado: (2023)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

Use of letermovir in umbilical cord blood transplantation based on risk scores
por: Rivera Franco, Monica M., et al.
Publicado: (2023)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative
por: Anthias, Chloe, et al.
Publicado: (2020)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

215b. Real-World Experience of Letermovir Use at an Academic Transplant Center
por: Ryu, HaYoung, et al.
Publicado: (2022)

2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
por: Xhemali, Xhilda, et al.
Publicado: (2023)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Improving the Postmarket Surveillance of Total Joint Arthroplasty Devices
por: Mahomed, Nizar N, et al.
Publicado: (2008)

Sleep-Walking with Zolpidem: Need for Continued Postmarketing Surveillance
por: Sharma, Ajitha, et al.
Publicado: (2015)

Descriptive analysis of postmarket surveillance data for hip implants
por: Pane, Josep, et al.
Publicado: (2020)

Postmarket Modifications of High-risk Plastic Surgery Devices
por: Olaiya, Oluwatobi R., et al.
Publicado: (2020)

Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Current development in medical devices postmarket surveillance in Taiwan
por: Lan, Cheng-Wen, et al.
Publicado: (2014)

Rumination and Rebound from Failure as a Function of Gender and Time on Task
por: Whiteman, Ronald C., et al.
Publicado: (2016)

Isavuconazole/letermovir/remdesivir: Drug-induced liver injury and off-label use: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l1c60o2p8jr95b6pmb8tvmai2u